洛杉磯–(BUSINESS WIRE)–(美國商業資訊) — Eyenuk, Inc.是全球性人工智慧(AI)醫療科技及服務公司，也是AI Eye Screening™在真實世界應用的領導者，該公司今天宣佈具有里程碑意義的前瞻性、多中心、樞紐臨床試驗的結果，該試驗是驗證其用於糖尿病視網膜病變(DR)自主檢測的EyeArt® AI眼科篩檢系統，DR是致盲性疾病，據估計，到2030年全球患病人數將達到1.91億人1。研究結果在ARVO眼科影像會議上發表報告，報告人是伊利諾大學芝加哥分校眼科Mari…
Author: Business Wire
Ophthalmology Times® Extends Nomination Deadline for 2019 Resident Writers Award Program
CRANBURY, N.J.–(BUSINESS WIRE)–Ophthalmology Times® Extends Nomination Deadline for 2019 Resident Writers Award Program
前瞻性、多中心、枢纽临床试验显示，Eyenuk用于糖尿病视网膜病变的人工智能眼病筛查系统有卓越表现
洛杉矶–(BUSINESS WIRE)–(美国商业资讯) — Eyenuk, Inc.是一家全球性人工智能(AI)医疗技术及服务公司，也是AI Eye Screening™在真实世界应用的领先者，该公司今天发布了其验证EyeArt® AI眼病筛查系统的里程碑前瞻性、多中心、枢纽临床试验的结果，该系统用于糖尿病视网膜病变(DR)的自主检测，DR是一种致盲性疾病，据估计，到2030年全球患病人数将达到1.91亿1。研究结果在ARVO眼成像会议上呈报，呈报人是伊利诺伊大学芝加哥分校眼科Marion …
Trividia Health, Inc. Announces Launch of TRUE A-G Scan™
FORT LAUDERDALE, Fla.–(BUSINESS WIRE)–Trividia Health Inc. announced today the launch of the TRUE A-G Scan™. The new product was presented this past week at NACDS Annual in Palm Beach, FL. The TRUE A-G Scan is a FDA cleared non-invasive, innovative, …
GenSight Biologics annonce la présentation des résultats à 72 semaines de l’étude de Phase III REVERSE avec GS010 au Congrès 2019 de l’American Academy of Neurology (AAN)
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, éligible PEA-PME), société biopharmaceutique dédiée à la découverte et au développement de thérapies géniques innovantes pour le traitement des maladies…
GenSight Biologics Announces Presentation of 72-Week Data from the REVERSE Phase III Trial of GS010 at the Annual Meeting of the American Academy of Neurology (AAN)
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central …
National Seating & Mobility to Distribute Independence Drive Wheelchair Eye Control Technology
NASHVILLE, Tenn.–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/acquisition?src=hash" target="_blank"gt;#acquisitionlt;/agt;–National Seating & Mobility (NSM), the leading provider of complex rehab…
Compulink Previews New User Interface for its Ophthalmology SMART EHR at ASCRS-ASOA 2019
NEWBURY PARK, Calif.–(BUSINESS WIRE)–Compulink previews new user interface for its Ophthalmology SMART EHR at ASCRS-ASOA 2019.
Eyenukの糖尿病網膜症向けAIアイ・スクリーニング・システムが前向き多施設ピボタル臨床試験で卓越した性能を証明
ロサンゼルス–(BUSINESS WIRE)–（ビジネスワイヤ） — 人工知能（AI）医療技術・サービスの世界的企業で、AIアイ・スクリーニング（AI Eye Screening™）向け実臨床アプリケーションのリーダー企業のEyenuk, Inc.は本日、EyeArt®（アイアート）AIアイ・スクリーニング・システムを対象に、糖尿病網膜症（DR）の自律的検出を検証した当社のランドマーク試験としての前向き多施設ピボタル臨床試験の結果を発表しました。失明病となるDRは、罹患者が2030年までに世界…
BioTime to Report First Quarter 2019 Financial Results and Provide Business Update on May 9, 2019
ALAMEDA, Calif.–(BUSINESS WIRE)–lt;a href="https://twitter.com/search?q=%24BTX&src=ctag" target="_blank"gt;$BTXlt;/agt; lt;a href="https://twitter.com/hashtag/AMD?src=hash" target=&quo…
Aerie Pharmaceuticals Announces Additional Undrawn $100M Credit Facility with Deerfield Management, Increasing Availability to $200M
DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle…
Aerie Pharmaceuticals Announces Additional Undrawn $100M Credit Facility with Deerfield Management, Increasing Availability to $200M
DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle…
CheckedUp Showcases Continued Point of Care Innovation with New Data at The Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
NEW YORK–(BUSINESS WIRE)–CheckedUp will present new data at the ARVO Annual Meeting on whether or not materials from their education platform are actually helping patients.
LENSAR® Laser System Receives FDA Clearance to Perform Micro Radial Incisions to Optimize Outcomes of Refractive Cataract Procedures
ORLANDO, Fla.–(BUSINESS WIRE)–LENSAR Laser System expands capabilities with micro radial incisions to allow surgeons to treat additional corneal conditions post cataract surgery.
BioTime Presents Updated Data from OpRegen® Phase I/IIa Clinical Study at the Association for Research in Vision and Ophthalmology Annual Meeting
ALAMEDA, Calif.–(BUSINESS WIRE)–lt;a href="https://twitter.com/search?q=%24BTX&src=ctag" target="_blank"gt;$BTXlt;/agt; lt;a href="https://twitter.com/hashtag/AMD?src=hash" target=&quo…
Ocular Therapeutix™ To Report First Quarter 2019 Financial Results
BEDFORD, Mass.–(BUSINESS WIRE)–lt;a href="https://twitter.com/search?q=%24OCUL&src=ctag" target="_blank"gt;$OCULlt;/agt; lt;a href="https://twitter.com/hashtag/OCUTX?src=hash" target=&…
Kala Pharmaceuticals to Report First Quarter 2019 Financial Results and Host Conference Call
WATERTOWN, Mass.–(BUSINESS WIRE)–Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) Drug Delivery Tec…
Aerpio Pharmaceuticals Presents Data Showing Potential of AKB-9778, a VE-PTP Inhibitor/Tie2 Activator, to Lower Intra-ocular Pressure in Human Subjects
CINCINNATI–(BUSINESS WIRE)–Aerpio Pharmaceuticals, Inc. (NASDAQ: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, presented data showing the potential of AKB-97…
Multiple Surgeons to Present Data on Glaukos Technologies at 2019 American Society of Cataract and Refractive Surgery
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies desig…
STAAR Surgical Announces Expanded Recommended Diopter Range for EVO Visian ICL by Refractive Societies in Germany and Japan
LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced the leading refractive ophthalmic societies in…